Citadel Advisors’s AnaptysBio ANAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $427K | Sell |
7,700
-17,500
| -69% | -$942K | ﹤0.01% | 9681 |
|
|
2025
Q4 | $1.22M | Sell |
25,200
-7,800
| -24% | -$304K | ﹤0.01% | 6962 |
|
|
2025
Q3 | $1.01M | Sell |
33,000
-11,600
| -26% | -$266K | ﹤0.01% | 7523 |
|
|
2025
Q2 | $990K | Buy |
44,600
+16,300
| +58% | +$341K | ﹤0.01% | 7113 |
|
|
2025
Q1 | $526K | Sell |
28,300
-70,700
| -71% | -$1.18M | ﹤0.01% | 8359 |
|
|
2024
Q4 | $1.31M | Buy |
99,000
+59,300
| +149% | +$1.44M | ﹤0.01% | 6485 |
|
|
2024
Q3 | $1.33M | Buy |
39,700
+33,500
| +540% | +$1.14M | ﹤0.01% | 6282 |
|
|
2024
Q2 | $155K | Buy |
6,200
+3,000
| +94% | +$69.9K | ﹤0.01% | 10300 |
|
|
2024
Q1 | $72.1K | Buy |
3,200
+200
| +7% | +$4.74K | ﹤0.01% | 11786 |
|
|
2023
Q4 | $64.3K | Buy |
3,000
+2,000
| +200% | +$34.5K | ﹤0.01% | 11504 |
|
|
2023
Q3 | $18K | Sell |
1,000
-1,100
| -52% | -$21K | ﹤0.01% | 12702 |
|
|
2023
Q2 | $42.7K | Buy |
2,100
+1,700
| +425% | +$34.5K | ﹤0.01% | 11995 |
|
|
2023
Q1 | $8.7K | Sell |
400
-100
| -20% | -$2.43K | ﹤0.01% | 13640 |
|
|
2022
Q4 | $15.5K | Sell |
500
-138,100
| -100% | -$3.9M | ﹤0.01% | 13323 |
|
|
2022
Q3 | $3.54M | Sell |
138,600
-7,100
| -5% | -$166K | ﹤0.01% | 4483 |
|
|
2022
Q2 | $2.96M | Buy |
145,700
+136,100
| +1,418% | +$3.01M | ﹤0.01% | 4779 |
|
|
2022
Q1 | $238K | Buy |
9,600
+1,800
| +23% | +$54.5K | ﹤0.01% | 11117 |
|
|
2021
Q4 | $271K | Sell |
7,800
-1,900
| -20% | -$60.3K | ﹤0.01% | 11133 |
|
|
2021
Q3 | $263K | Sell |
9,700
-12,700
| -57% | -$322K | ﹤0.01% | 11350 |
|
|
2021
Q2 | $581K | Sell |
22,400
-4,100
| -15% | -$98.3K | ﹤0.01% | 9712 |
|
|
2021
Q1 | $571K | Buy |
+26,500
| New | +$669K | ﹤0.01% | 9390 |
|
|
2020
Q2 | – | Sell |
-10,800
| Closed | -$153K | – | 9715 |
|
|
2020
Q1 | $153K | Sell |
10,800
-12,300
| -53% | -$187K | ﹤0.01% | 8274 |
|
|
2019
Q4 | $375K | Sell |
23,100
-18,200
| -44% | -$430K | ﹤0.01% | 7250 |
|
|
2019
Q3 | $1.45M | Buy |
41,300
+30,400
| +279% | +$1.45M | ﹤0.01% | 4985 |
|
|
2019
Q2 | $615K | Sell |
10,900
-1,900
| -15% | -$137K | ﹤0.01% | 6491 |
|
|
2019
Q1 | $935K | Buy |
12,800
+8,100
| +172% | +$559K | ﹤0.01% | 5712 |
|
|
2018
Q4 | $300K | Sell |
4,700
-171,100
| -97% | -$12.7M | ﹤0.01% | 7271 |
|
|
2018
Q3 | $17.5M | Buy |
175,800
+161,000
| +1,088% | +$13.4M | 0.01% | 1516 |
|
|
2018
Q2 | $1.05M | Sell |
14,800
-26,900
| -65% | -$2.26M | ﹤0.01% | 5134 |
|
|
2018
Q1 | $4.34M | Buy |
41,700
+37,100
| +807% | +$4.18M | ﹤0.01% | 2620 |
|
|
2017
Q4 | $463K | Buy |
+4,600
| New | +$339K | ﹤0.01% | 5771 |
|
Other funds holding ANAB
EC
TCM
AAA
VCM
PAI
6CM
Citadel Advisors's ANAB Position: Q1 2026 in Review
Citadel Advisors increased its AnaptysBio (ANAB) stake by 113% in Q1 2026, buying an estimated $6.67M and bringing the position to 233,450 shares worth $12.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2880.
Citadel Advisors first reported a position in ANAB in Q3 2017 and has held it in 32 quarters since. The position peaked at $64.8M in Q3 2018. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.
- Citadel Advisors held 233,450 shares of AnaptysBio worth $12.9M as of Q1 2026.
- Citadel Advisors bought 123,967 AnaptysBio shares in Q1 2026, an estimated $6.67M.
- AnaptysBio made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2880 holding.
- Citadel Advisors first reported a position in AnaptysBio in Q3 2017 and has held it in 32 quarters since.
- Citadel Advisors's AnaptysBio position peaked at $64.8M in Q3 2018.
- 207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.